FDA should consider the significant public health issues, especially for youth, created by PMI co-marketing of its Swedish Match General Snus and ZYN oral nicotine products and not reauthorize modified risk claims for General Snus

My colleagues at UCSF and I submitted this comment to the FDA Tobacco Products Scientific Advisory Committee opposing extension of PMI’s current authorization to make modified risk claims because its co-marketing with its ZYN nicotine pouch is fundamentally misleading. TPSAC is holding a meeting to discuss the modified risk request on June 26, 2024. AContinue reading “FDA should consider the significant public health issues, especially for youth, created by PMI co-marketing of its Swedish Match General Snus and ZYN oral nicotine products and not reauthorize modified risk claims for General Snus”